The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Sep. 27, 4:40 AM

Slide #14. Aquinox Pharmaceuticals, Inc. Secondary Offering

Company: Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)
Date announced: 9/19/2016
Shares Offered: 5,350,000
Date of Pricing: 9/19/2016
Price Per Share: $12.25
Secondary Offering Details: Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it intends to offer and sell, subject to market and other conditions, an underwritten public offering of its common stock. In connection with this offering, Aquinox expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15% of the shares sold in the offering, on the same terms and conditions. All of the shares are being offered by Aquinox. This offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 9/19- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced the pricing of an underwritten public offering of 5,350,000 shares of its common stock at a price to the public of $12.25 per share. In addition, Aquinox has granted the underwriters a 30-day option to purchase up to 802,500 additional shares of common stock at the public offering price. The offering is expected to close on September 23, 2016, subject to customary closing conditions.

Aquinox Pharmaceuticals is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Co.'s primary focus is anti-inflammatory product candidates targeting the SH2-containing inositol-5'-phosphatase 1 (SHIP1) enzyme, which is a primary regulator of a cellular signaling pathway in immune cells, known as the PI3K pathway. Co.'s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Co. is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder.
Open the AQXP Page at The Online Investor »

Company Name:  Aquinox Pharmaceuticals Inc
Website:  www.aqxpharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AQXP:  5
Total Market Value Held by ETFs:  $3.49M
Total Market Capitalization:  $258.00M
% of Market Cap. Held by ETFs:  1.35%
 

Open the AQXP Page at The Online Investor (in a new window) »

September 27, 2016    4:40 AM Eastern
Quotes delayed 20 minutes



Buy (3.00 out of 4)
50th percentile
(ranked higher than approx. 50% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.